The Satiety Hormones: GLP-1, PYY, and CCK Explained Simply

The instruction to stop eating arrives in the brain through several converging channels — but most of the chemical signalling that says this meal was enough comes from three hormones released by cells in the gut. They are not the only satiety signals the body uses, but they are the dominant ones, the most precisely characterised, and the ones that GLP-1 medications imitate.

Each fires at a different point in the meal. Each carries a slightly different message. When all three work as designed, eating tends to stop on its own at appropriate intake. When one or more of them under-fires — as happens with ultra-processed foods, in some obesity phenotypes, and after sustained dieting — the meal ends without the brain registering that it should be over.

CCK: the first signal

Cholecystokinin — CCK for short — was the first gut satiety hormone identified, and it sets the timing for everything that follows. CCK is released by I-cells in the duodenum and upper small intestine within minutes of fat and protein entering from the stomach. The peak typically occurs around 15 to 30 minutes into a meal.

Rosalyn Liddle at the University of California, San Francisco, published the first reliable human assay for CCK in the mid-1980s and used it to demonstrate the close correspondence between rising CCK and subjective fullness. Her work established what later research confirmed: CCK signals the brain through the vagus nerve to slow gastric emptying and reduce the drive to keep eating. The signal is local, fast, and meal-by-meal.

Two consequences follow practically. First, meals that are very low in fat and protein release less CCK and produce a weaker satiety signal — part of why a salad without dressing or a piece of fruit alone often fails to feel like enough. Second, eating very quickly outpaces the CCK release; the meal is over before the signal arrives, leading to the familiar pattern of feeling full ten minutes after stopping rather than during the meal.

PYY: the medium-term signal

Peptide YY is released by L-cells in the lower small intestine and colon, with peak levels arriving roughly 60 to 90 minutes after eating. PYY's job is to extend satiety into the post-meal hours — the period during which CCK is already fading but the body needs to register that it is no longer in a feeding state.

Stephen Bloom at Imperial College London is the dominant figure in PYY research. His 2002 study in Nature showed that infusing PYY3-36, the active form of the hormone, into healthy and obese volunteers reduced food intake at a subsequent meal by roughly a third. The effect held across body weights, suggesting that the satiety machinery itself could be engaged even in obesity — the signal just wasn't firing strongly enough endogenously.

PYY release scales with caloric load and is particularly responsive to protein and to soluble fibre. Meals that contain neither, or contain primarily refined carbohydrate, produce blunted PYY responses. This is part of why ultra-processed foods leave people hungry shortly after eating: the post-meal satiety extension never properly switches on.

What ultra-processed food does to PYY

Kevin Hall's 2019 inpatient feeding trial at the National Institutes of Health found that participants on an ultra-processed diet ate roughly 508 more calories per day than on a matched unprocessed diet, even though sugar, fat, fibre, and sodium were equalised. Several mechanisms appear to contribute, but blunted PYY response is a plausible candidate. Ultra-processed foods are eaten faster, are calorie-dense per unit volume, and tend to engage the gut's satiety machinery less effectively than whole foods of equivalent composition. The hormone fires, but at a level that doesn't shut down the next meal.

GLP-1: the satiety signal that became a medication

Glucagon-like peptide-1 is co-released with PYY by the same L-cells in the lower small intestine. It fires within minutes of food reaching the distal gut, peaks around an hour after eating, and acts on receptors in the hypothalamus, the brainstem, and — as Daniel Drucker at the University of Toronto has spent decades demonstrating — throughout the central nervous system.

GLP-1 does more than signal satiety. It slows gastric emptying (extending the felt sense of fullness from the stomach), enhances insulin release in response to glucose, and — through receptors in the reward circuitry — modulates the brain's response to food cues. The breadth of its action is why GLP-1 became the basis for the most effective pharmacological approach to obesity in decades.

Endogenous GLP-1 has a very short half-life — degraded within minutes by the enzyme DPP-4 — which limits the duration of the natural signal. Semaglutide and tirzepatide are engineered to resist this degradation, extending the satiety signal from minutes to days. That is the mechanistic move behind the entire GLP-1 receptor agonist class.

How the three hormones work together

A well-functioning meal triggers a sequence:

• Food enters the stomach; stretch receptors send early fullness signals through the vagus nerve.
• Within 15 minutes, fat and protein reach the duodenum and trigger CCK release — the first chemical "enough" signal.
• Around 30 to 60 minutes in, food reaches the distal small intestine and triggers GLP-1 and PYY release — the sustained satiety phase.
• Ghrelin, which had been rising before the meal, falls sharply once eating begins and remains suppressed for hours.

The brain integrates these signals against a background reading of energy stores (mediated largely by leptin) and decides whether to continue food-seeking behaviour. When the system works, the answer is no until the next meal cycle. When one or more signals are blunted — by food composition, by leptin resistance, by dieting-induced hormonal shifts — the answer is yes much sooner.

Why GLP-1 medications are not just appetite suppressants

The term "appetite suppressant" frames GLP-1 medications as something that pushes hunger down. The mechanism is more accurately described as restoring satiety signalling to a state the dysregulated system no longer reliably produces. Semaglutide activates receptors that the endogenous hormone activates briefly; the engineered molecule simply keeps the signal on. Tirzepatide activates both GLP-1 and GIP receptors, broadening the signal.

The clinical observation that patients describe — eating reasonable portions and feeling done, without the constant pull back toward food — corresponds to what the gut hormone signalling was supposed to produce in the first place. The intervention is not foreign to the system. It is the system, sustained.

What this means for eating without medication

For anyone managing appetite without pharmacological help, the gut hormone biology suggests several practical handles. Eating slowly gives CCK time to arrive before the meal is over. Including protein and soluble fibre in every meal engages PYY more reliably than refined carbohydrate alone. Whole foods of varied texture engage the satiety apparatus more than ultra-processed equivalents. Sufficient sleep keeps the broader hormonal environment from drifting toward hunger.

These help — though they tend to help less in people whose satiety machinery is significantly dysregulated. For those situations, GLP-1 medications address the mechanism directly.

Key takeaways

• Three gut hormones — CCK, PYY, and GLP-1 — carry most of the chemical satiety signalling from gut to brain after a meal.
• CCK fires first (15–30 minutes), triggered by fat and protein reaching the duodenum; eating too quickly outpaces it.
• PYY extends satiety for 60–90 minutes after eating; its release scales with protein and soluble fibre.
• GLP-1 acts on the hypothalamus, brainstem, and reward circuitry — broader than the other two, with effects beyond simple appetite suppression.
• Ultra-processed foods produce blunted satiety hormone responses, contributing to higher spontaneous calorie intake.
• GLP-1 receptor agonists extend a signal that the endogenous hormone produces only briefly — they don't introduce a foreign action.